Northwestern Mutual Wealth Management Co. Buys 7,059 Shares of Abbott Laboratories $ABT

Northwestern Mutual Wealth Management Co. grew its position in shares of Abbott Laboratories (NYSE:ABT) by 2.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 255,295 shares of the healthcare product maker’s stock after purchasing an additional 7,059 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Abbott Laboratories were worth $23,165,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Nia Impact Advisors LLC grew its holdings in Abbott Laboratories by 2.2% during the 2nd quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock valued at $504,000 after buying an additional 79 shares in the last quarter. Riggs Asset Managment Co. Inc. raised its holdings in shares of Abbott Laboratories by 9.3% during the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 1,031 shares of the healthcare product maker’s stock worth $140,000 after acquiring an additional 88 shares in the last quarter. Eley Financial Management Inc boosted its position in shares of Abbott Laboratories by 0.9% during the 4th quarter. Eley Financial Management Inc now owns 10,817 shares of the healthcare product maker’s stock valued at $1,355,000 after acquiring an additional 92 shares during the last quarter. Copley Financial Group Inc. increased its position in Abbott Laboratories by 2.1% in the fourth quarter. Copley Financial Group Inc. now owns 4,435 shares of the healthcare product maker’s stock worth $556,000 after purchasing an additional 93 shares during the last quarter. Finally, Kelleher Financial Advisors raised its stake in Abbott Laboratories by 2.9% during the third quarter. Kelleher Financial Advisors now owns 3,301 shares of the healthcare product maker’s stock valued at $442,000 after purchasing an additional 93 shares in the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Abbott Laboratories Trading Down 0.5%

NYSE:ABT opened at $108.29 on Friday. The firm has a 50-day simple moving average of $104.43 and a 200-day simple moving average of $100.12. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The firm has a market cap of $187.38 billion, a P/E ratio of 35.05, a P/E/G ratio of 2.02 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. The firm had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company’s quarterly revenue was up 13.0% on a year-over-year basis. During the same period last year, the firm earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date was Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is 81.55%.

Analysts Set New Price Targets

A number of analysts have recently weighed in on ABT shares. JPMorgan Chase & Co. boosted their target price on shares of Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. BTIG Research boosted their price objective on Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. UBS Group lowered their price objective on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. Piper Sandler reissued an “overweight” rating and set a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Finally, Wells Fargo & Company lifted their price objective on shares of Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $119.50.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.